Preclinical Pharmacokinetic/Pharmacodynamic Modeling and Simulation in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape
Journal Title: The AAPS Journal - Year 2015, Vol 17, Issue 2
Abstract
The application of modeling and simulation techniques is increasingly common in preclinical stages of the drug discovery and development process. A survey focusing on preclinical pharmacokinetic/pharmacodynamics (PK/PD) analysis was conducted across pharmaceutical companies that are members of the International Consortium for Quality and Innovation in Pharmaceutical Development. Based on survey responses, ~68% of companies use preclinical PK/PD analysis in all therapeutic areas indicating its broad application. An important goal of preclinical PK/PD analysis in all pharmaceutical companies is for the selection/optimization of doses and/or dose regimens, including prediction of human efficacious doses. Oncology was the therapeutic area with the most PK/PD analysis support and where it showed the most impact. Consistent use of more complex systems pharmacology models and hybrid physiologically based pharmacokinetic models with PK/PD components was less common compared to traditional PK/PD models. Preclinical PK/PD analysis is increasingly being included in regulatory submissions with ~73% of companies including these data to some degree. Most companies (~86%) have seen impact of preclinical PK/PD analyses in drug development. Finally, ~59% of pharmaceutical companies have plans to expand their PK/PD modeling groups over the next 2 years indicating continued growth. The growth of preclinical PK/PD modeling groups in pharmaceutical industry is necessary to establish required resources and skills to further expand use of preclinical PK/PD modeling in a meaningful and impactful manner.
Authors and Affiliations
Edgar Schuck, Tonika Bohnert, Arijit Chakravarty, Valeriu Damian-Iordache, Christopher Gibson, Cheng-Pang Hsu, Tycho Heimbach, Anu Shilpa Krishnatry, Bianca M Liederer, Jing Lin, Tristan Maurer, Jerome T Mettetal, Daniel R Mudra, Marjoleen JMA Nijsen, Joseph Raybon, Patricia Schroeder, Virna Schuck, Satyendra Suryawanshi, Yaming Su, Patrick Trapa, Alice Tsai, Majid Vakilynejad, Shining Wang, Harvey Wong
Keywords
Related Articles
- EP ID EP680933
- DOI 10.1208/s12248-014-9716-2
- Views 45
- Downloads 0
Properties of microcrystalline cellulose and powder cellulose after extrusion/spheronization as studied by fourier transform Raman spectroscopy and environmental scanning electron microscopy
In this study, the effect of powder cellulose (PC) and 2 types of microcrystalline cellulose (MCC 101 and MCC 301) on pellet properties produced by an extrusion/spheronization process was investigated. The different inve...
DNA-based therapeutics and DNA delivery systems: A comprehensive review
The past several years have witnessed the evolution of gene medicine from an experimental technology into a viable strategy for developing therapeutics for a wide range of human disorders. Numerous prototype DNA-based bi...
Design and Evaluation of Thioalkylated Mannose-Modified Dendrimer (G3)/α-Cyclodextrin Conjugates as Antigen-Presenting Cell-Selective siRNA Carriers
The online version of this article (doi:10.1208/s12248-014-9665-9) contains supplementary material, which is available to authorized users.
International Guidelines for Bioequivalence of Locally Acting Orally Inhaled Drug Products: Similarities and Differences
The online version of this article (doi:10.1208/s12248-015-9733-9) contains supplementary material, which is available to authorized users.
Emerging Insights for Translational Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Studies: Towards Prediction of Nose-to-Brain Transport in Humans
To investigate the potential added value of intranasal drug administration, preclinical studies to date have typically used the area under the curve (AUC) in brain tissue or cerebrospinal fluid (CSF) compared to plasma f...